艾司西酞普兰联合多巴丝肼治疗帕金森病的临床效果及对炎症因子的影响  

Clinical Effects of Escitalopram Combined with Dopasin on Patients with Parkinson’s Disease and its Effects on Inflammatory Factors

作　　者：胡乔 向明清[1] 郭才华 汪华[1] HU Qiao;XIANG Mingqing;GUO Caihua;WANG Hua(Dept.of Internal Medicine-Neurology,Jingzhou the First People’s Hospital,Hubei Jingzhou 434000,China)

机构地区：[1]荆州市第一人民医院神经内科,湖北荆州434000

出　　处：《中国医院用药评价与分析》2021年第1期41-44,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：荆州市科学计划项目(No.20190927100916)。

摘　　要：目的:探讨艾司西酞普兰联合多巴丝肼治疗帕金森病的临床效果及对炎症因子的影响。方法:选取2018年4月至2019年12月荆州市第一人民医院收治的帕金森病患者138例,采用完全随机数法分为对照组和观察组,每组69例。对照组患者给予多巴丝肼治疗,观察组患者在对照组的基础上联合艾司西酞普兰治疗。观察两组患者汉密尔顿抑郁量表(Hamilton depression scale,HAMD)、统一帕金森病评分量表(unified Parkinson’s disease rating scale,UPDRS)、汉密尔顿焦虑量表(Hamilton anxiety scale,HAMA)及韦氏记忆量表(Wechsler memory Scale,WMS)评分,炎症因子水平、临床疗效及不良反应发生情况。结果:治疗后,观察组患者的HAMD、UPDRS和HAMA评分明显低于对照组,WMS评分明显高于对照组,炎症因子水平明显低于对照组,差异均有统计学意义(P<0.05)。观察组患者的总有效率为95.65%(66/69),明显高于对照组的82.61%(57/69),差异有统计学意义(P<0.05)。观察组患者的不良反应发生率为11.59%(8/69),略高于对照组的7.25%(5/69),但两组比较的差异无统计学意义(P>0.05)。结论:艾司西酞普兰联合多巴丝肼可有效改善帕金森病患者的临床症状,抑制机体炎症反应,修复受损神经,效果显著。OBJECTIVE:To explore the clinical effects of escitalopram combined with dopasin on patients with Parkinson’s disease and its effects on inflammatory factors.METHODS:Totally 138 patients with Parkinson‘s disease admitted into Jingzhou the First People’s Hospital from Apr.2018 to Dec.2019 were extracted to be divided into the control group and the observation group,with 69 cases in each group.The control group was treated with dopasizide,while the observation group received escitalopram on the basis of the control group.Hamilton depression scale(HAMD),unified Parkinson’s disease rating scale(UPDRS),Hamilton anxiety scale(HAMA)and Wechsler memory scale(WMS)scores,inflammation factor levels,clinical efficacy and adverse drug reactions of two groups were observed.RESULTS:HAMD,UPDRS and HAMA scores of the observation group were significantly lower than those of the control group,WMS scores were significantly higher than those of the control group,and inflammatory factors were significantly lower than those of the control group,the differences were statistically significant(P<0.05).The total effective rate in the observation group was 95.65%(66/69),significantly higher than 82.61%(57/69)in the control group,with statistically significant difference(P<0.05).The incidence of adverse drug reactions in the observation group was 11.59%(8/69),slightly higher than that in the control group 7.25%(5/69),yet the difference was not statistically significant(P>0.05).CONCLUSIONS:Escitalopram combined with dopamine can effectively improve the clinical symptoms of patients with Parkinson’s disease,inhibit the inflammatory response and repair damaged nerves.

关 键 词：艾司西酞普兰 多巴丝肼 帕金森病 炎症因子 

分 类 号：R971[医药卫生—药品]